Trials / Completed
CompletedNCT01710852
Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation
A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients With Paroxysmal Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate whether treatment with ISIS CRP Rx can reduce AF (Atrial Fibrillation) burden (percentage of time spent in AF) in subjects with paroxysmal AF
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS CRP Rx | |
| DRUG | Placebo |
Timeline
- Start date
- 2012-10-01
- Primary completion
- 2014-04-01
- Completion
- 2014-04-01
- First posted
- 2012-10-19
- Last updated
- 2015-08-26
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT01710852. Inclusion in this directory is not an endorsement.